Penn spinout Vittoria Biotherapeutics emerges from stealth mode with $10M seed round

The new company hopes to overcome the current limitations of CAR T-cell therapeutics by using unique cell engineering and gene editing technologies.
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.